ALPHA JECT 6-2 injeksjonsvæske, emulsjon, vaksine til atlantisk laks

Authorised

- Infectious pancreatic necrosis virus, serotype Sp, Inactivated
- Moritella viscosa, Inactivated
- Vibrio anguillarum, serotype O2a, Inactivated
- Vibrio anguillarum, serotype O1, Inactivated
- Aliivibrio salmonicida, Inactivated
- Aeromonas salmonicida, subsp. salmonicida, Inactivated

Product identification

Medicine name:
ALPHA JECT 6-2 injeksjonsvæske, emulsjon, vaksine til atlantisk laks

Active substance:
Infectious pancreatic necrosis virus, serotype Sp, Inactivated

Moritella viscosa, Inactivated

Vibrio anguillarum, serotype O2a, Inactivated

Vibrio anguillarum, serotype O1, Inactivated

Aliivibrio salmonicida, Inactivated

Aeromonas salmonicida, subsp. salmonicida, Inactivated

Target species:
Atlantic salmon

Route of administration:

Intraperitoneal use

Product details

Active substance and strength:

Infectious pancreatic necrosis virus, serotype Sp, Inactivated
0.20 antigen unit(s) / 0.10 millilitre(s)

Moritella viscosa, Inactivated
60.00 Relative Percentage Survival / 0.10 millilitre(s)

Vibrio anguillarum, serotype O2a, Inactivated
75.00 Relative Percentage Survival / 0.10 millilitre(s)

Vibrio anguillarum, serotype O1, Inactivated
75.00 Relative Percentage Survival / 0.10 millilitre(s)

Aliivibrio salmonicida, Inactivated
90.00 Relative Percentage Survival / 0.10 millilitre(s)

Aeromonas salmonicida, subsp. salmonicida, Inactivated
80.00 Relative Percentage Survival / 0.10 millilitre(s)

Pharmaceutical form:

Emulsion for injection

Withdrawal period by route of administration:

Intraperitoneal use:

- **Atlantic salmon**
  - Meat and offal. 0 degree day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI10AL02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:
Norway

Package description:
Available only in Norwegian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Pharmaq AS

Marketing authorisation date:
6/07/2010

Manufacturing sites for batch release:
Pharmaq AS

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
02-1370

Date of authorisation status change:
16/01/2015

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.